BioInvent International AB earnings date
BioInvent International AB (BIX0) Q3 2026 Earnings Report
DE:BIX0 Q3 2026 EPS Results
- Actual EPS
- -EUR 0.16
- Consensus EPS
- -EUR 0.18
- Beat/Miss
- Beat by +EUR 0.02
- One Year Ago EPS
- -EUR 0.18
DE:BIX0 Q3 2026 Revenue Results
- Actual Revenue
- EUR 980.50K
- Expected Revenue
- EUR 727.59K
- Beat/Miss
- Beat by +EUR 252.92K
- YoY Revenue Growth
- +224.99%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 10/29/2026
- Time
- Before Open
- Conference Call
- Thursday, October 29, 2026
BioInvent International AB's next earnings date is estimated for March 4, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was predominantly positive, supported by encouraging BI-1808 response and progression-free survival data, FDA Fast Track designations, an ESMO Best Poster Award, planned randomized development, and a potentially extended cash runway through the end of 2027 if the covered portion of the rights issue is completed. The company nevertheless reported a substantial net loss, a sharp year-to-date sales decline due largely to the prior-year milestone comparison, planned workforce reductions, dependence on financing and partnering, and delays in BI-1206 data maturation.
BioInvent said BI-1808 phase I/IIa Part C is about to start in Q1 2027, with randomized three arms with 20 patients each: BI-1808 at 1,000 milligram and 500 milligram, and the control, all with pembrolizumab and a weekly paclitaxel plus minus bevacizumab; first data is expected for the second half of 2027, with a target of a 60% objective response rate and a three-five months increase in PFS, while later modeling expects at least three months addition to PFS and somewhere around a high 50% or 60%, maybe we will get over that bar for objective response rate. Bevacizumab is expected to be used in the order of 70% of the patients, with arms equilibrated for usage. The company expects to complete BI-1808 CTCL dose optimization and prepare for a potential pivotal study during the second half of next year with a partner, and expects the first readout of BI-1206 in first-line non-small cell lung cancer and uveal melanoma in first half 2027. The rights issue targets SEK 430 million gross, with SEK 350 million covered, and the expected cash runway is to end of 2027; up to 20 FTEs may be reduced.
- BI-1808 Received FDA Fast Track DesignationBI-1808 received FDA Fast Track designation in early August 2026 for recurring ovarian cancer. The program also has Fast Track designation for relapsed or refractory mycosis fungoides and Sézary syndrome, reflecting a high unmet medical need.
- Positive BI-1808 Clinical Recognition and PublicationsThe BI-1808 plus Keytruda ovarian cancer data presented at ESMO received the Best Poster Award in the investigational immunotherapy section. BioInvent also published BI-1808 scientific work in Cancer Research and Clinical Cancer Research, including the first-in-human data and the program's mode of action.
- BI-1808 Demonstrated Responses in Heavily Pretreated Ovarian CancerIn the ESMO dataset, BI-1808 plus pembrolizumab produced one complete response and seven partial responses, with a 24% objective response rate and 53% disease control rate. Several patients remained stable for more than 10 months, and six patients were still on treatment at the September cutoff.
- BI-1808 Showed Favorable Treatment Discontinuation and PFS MetricsAmong 81 solid-tumor patients, treatment-related discontinuation was less than 5%. Median progression-free survival was 10.3 months by iRECIST and 4.1 months by RECIST. Management compared these results with a 2.1-month progression-free survival figure for pembrolizumab alone in KEYNOTE-100, while noting that this was an indirect comparison and involved a different study.
- BI-1808 Combination Outperformed Individual Components on ORRIn the recurring ovarian cancer analysis, the BI-1808 and pembrolizumab combination had a 24% objective response rate, compared with 8% for pembrolizumab alone and 6% for BI-1808 alone.
- Planned Randomized BI-1808 Part C StudyThe Phase I/IIa Part C study is expected to start in Q1 2027 and will include three randomized arms with 20 patients each. The study will evaluate BI-1808 at 1,000 milligrams and 500 milligrams, alongside a control, with pembrolizumab and weekly paclitaxel plus or minus bevacizumab. Initial data are expected in the second half of 2027.
- Management Identified Meaningful BI-1808 Efficacy TargetsManagement said its modeling assumes a three-to-five-month increase in progression-free survival for the planned triplet combination and is targeting a 60% objective response rate. In a later discussion, management referenced a high-50% to 60% objective response rate as a potential benchmark and said the key differentiation would be progression-free survival.
- Recruitment Progress and Study Design for Part CThe company plans to use the same patient population as KEYNOTE-B96, allowing only two previous lines of treatment. Investigators expressed enthusiasm about the study and requested site openings. Bevacizumab will be used at investigator discretion, with management expecting usage similar to KEYNOTE-B96, where approximately 70% of patients received it; study arms will be equilibrated for bevacizumab use.
- CTCL Development ProgressBioInvent plans to complete Phase IIa dose optimization for BI-1808 as a monotherapy in CTCL and position the program for a potential pivotal study in the second half of 2027. Management said the pivotal study should be conducted with a partner.
- BI-1206 Clinical Readouts and Partnering ActivitiesThe company expects first readouts for BI-1206 plus Keytruda in first-line non-small cell lung cancer and uveal melanoma in the first half of 2027. Recruitment was described as good, with the uveal melanoma portion recruited and at least one-third of the non-small cell lung cancer cohort recruited. BioInvent has engaged an external organization to support partnering discussions for BI-1206 and has begun discussions around BI-1808.
- BI-1206 Non-Hodgkin Lymphoma Follow-UpBioInvent is completing follow-up and data analysis in non-Hodgkin lymphoma and plans to discuss the final dataset with companies that have previously engaged with the company. Management said partnering discussions could address non-Hodgkin lymphoma, solid tumors, or both.
- Rights Issue Has Significant Secured SupportThe board proposed a rights issue of approximately SEK 430 million gross, subject to Extraordinary General Meeting approval. Subscription commitments of SEK 80 million and guarantee undertakings of SEK 270 million provide total coverage of SEK 350 million of the gross proceeds.
- Rights Issue Expected to Extend Cash RunwayBased on SEK 225 million of liquid funds and current investments at the end of September, the company is financed into the latter part of Q1 2027. Completion of the SEK 350 million portion covered by commitments and guarantees is expected to extend the cash runway to the end of 2027. Full subscription would provide additional financial flexibility for prioritized clinical programs.
- Quarterly Net Sales IncreasedQ3 2026 net sales were SEK 10.8 million versus SEK 3.3 million in Q3 2025, an increase of SEK 7.5 million, or approximately 227%. The increase was related to higher production of antibodies for customers.
- Operating Costs DecreasedQ3 operating costs decreased from SEK 137 million in Q3 2025 to SEK 131 million in Q3 2026, a reduction of SEK 6 million, or approximately 4.4%. For the first nine months, operating costs decreased from SEK 446 million to SEK 404 million, a reduction of SEK 42 million, or approximately 9.4%.
- Prioritized Pipeline FocusThe company is prioritizing BI-1808 first and BI-1206 second, while continuing to advance other priority clinical and preclinical projects. Management described TNFR2 and Epstein-Barr virus B as first-in-class oncology targets and said the rights issue is intended to take BI-1808 into randomized and potentially pivotal studies while continuing BI-1206 development with a partner.
DE:BIX0 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 04, 2027 | 2026 (Q4) | -0.10- | -0.17 | ― | ― |
| Oct 29, 2026 | 2026 (Q3) | -0.18-0.16 | -0.18 | 7.99% (+0.01) | |
| Aug 27, 2026 | 2026 (Q2) | -0.17-0.17 | 0.05 | -416.61% (-0.22) | |
| Apr 29, 2026 | 2026 (Q1) | -0.17-0.17 | -0.16 | -7.39% (-0.01) | |
| Feb 26, 2026 | 2025 (Q4) | ―-0.17 | -0.16 | -7.55% (-0.01) | |
| Oct 29, 2025 | 2025 (Q3) | ―-0.18 | -0.13 | -32.88% (-0.04) | |
| Aug 26, 2025 | 2025 (Q2) | ―0.05 | -0.19 | 128.27% (+0.24) | |
| Apr 29, 2025 | 2025 (Q1) | ―-0.16 | -0.11 | -49.66% (-0.05) | |
| Feb 27, 2025 | 2024 (Q4) | ―-0.16 | -0.13 | -20.33% (-0.03) | |
| Oct 31, 2024 | 2024 (Q3) | ―-0.13 | -0.1 | -36.85% (-0.04) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
